June 8 , 2010
BREVAGen™ Pharmacoeconomic Data Presented at ASCO 2010 in Chicago
Pharmacoeconomic data supporting GTG’s recently acquired global breast cancer risk test
BREVAGen™ has been presented in an Abstract at the 2010 Annual Meeting of the American
Society of Clinical Oncology in Chicago.
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) announces that pharmacoeconomic
data pertaining to the BREVAGen™ test, modelled and compiled by Archimedes Inc., has been
presented as an Abstract at the 2010 Annual Meeting of the American Society of Clinical Oncology
(ASCO) in Chicago, Illinois. A copy of the Abstract can be downloaded at
http://abstract.asco.org/AbstView_74_42880.html. These results have also been published in the
Journal of Clinical Oncology J Clin Oncol 28:7s, 2010 (suppl; abstr 6042) .
Archimedes Inc. is healthcare modelling organization located in San Francisco
(http://archimedesmodel.com). Their core technology - the Archimedes Model - is a mathematical
model of human physiology, diseases, interventions and healthcare systems which has been developed
and in collaboration with the American Cancer Society. The Model is highly detailed, rigorously
validated and can run a virtual clinical trial with 1,000,000 people, spanning 30 years of life, in three
hours to help understand and resolve vital clinical and administrative healthcare questions.
In this study, the Archimedes Model has been used to forecast costs and clinical outcomes resulting
from breast cancer risk testing using BREVAGen™ followed by preventative therapy in a population
of women who are an intermediate risk of developing breast cancer. The Model compares this with
costs and clinical outcomes resulting from no treatment, to provide output in terms of Quality-
Adjusted Life Years (QALYs), an arithmetic product of quality and quantity of life equivalent to one
full year of life in good health. QALYs were derived from comparing BREVAGen’s™ role in
directing preventative tamoxifen